MIF analysis demonstrated an overall increase in proliferative CD4+ T cells following combination therapy, whereas the vehicle control group showed an increase in Treg abundance across all regions of the tumor, with the most pronounced increase at the tumor border (0–200) (Figure 6F). The gene discussed is MIF; the disease is neoplasm.